leisure time -WSS

leisure time

author：entertainment 2025-09-27 12:43:08 - browse：2615

AI skin cancer detector, dermasensor. -- health tech coverage from STAT — Around 5 million skin cancers are diagnosed each year in the United States. Skin cancer is common, but it’s also not that deadly when caught early. Courtesy DermaSensor

The Food and Drug Administration cleared an AI-powered device for detecting skin cancer on Wednesday, giving primary care physicians a new way to evaluate troubling skin spots.

Around 5 million skin cancers are diagnosed each year in the United States. Skin cancer is common, but most types are not that deadly when caught early.

The device, developed by a small company called DermaSensor, is handheld and uses light to examine suspicious moles on a cellular level. It will be marketed specifically for primary care physicians to use in routine check-ups in patients aged 40 and above.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： What it’s like to watch children die of measles

Wikipedia

WSS

Weight loss drug costs may need more research, senator suggests

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Air quality improving but still lags in Black, Hispanic communities

Precocious puberty in girls comes with mental health risks

entertainment

leisure time

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Hospitals look to new technology to keep health care workers safe

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Why medical students are struggling with mental health

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Amylyx ALS drug failure raises questions and concerns

In age of alternative facts, a scholarly course on calling out crap

Weight loss drug costs may need more research, senator suggests

As demand for Covid shots wanes, Moderna seeks its next success

A daunting task: navigating dual Medicare, Medicaid eligibility

hotspot